HST Global, Inc. (HSTC)
USD 0.83
(0.0%)
USD 0.83
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1526.00 USD | 703.16% |
| 2022 | 190.00 USD | -15.56% |
| 2021 | 225.00 USD | -65.91% |
| 2020 | 660.00 USD | -66.24% |
| 2019 | 1955.00 USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 291.00 USD | -37.42% |
| 2016 | 465.00 USD | 138.46% |
| 2015 | 195.00 USD | 18.9% |
| 2014 | 164.00 USD | -28.7% |
| 2013 | 230.00 USD | -81.18% |
| 2012 | 1222.00 USD | 167.98% |
| 2011 | 456.00 USD | -56.53% |
| 2010 | 1049.00 USD | -84.62% |
| 2009 | 6819.00 USD | 112.43% |
| 2008 | 3210.00 USD | -99.83% |
| 2007 | 1.9 Million USD | -90.99% |
| 2006 | 21.11 Million USD | 3728.53% |
| 2005 | 551.47 Thousand USD | 2270.83% |
| 2004 | 23.26 Thousand USD | 147.01% |
| 2003 | 9417.00 USD | -99.29% |
| 2002 | 1.33 Million USD | 3137.76% |
| 2001 | 41.2 Thousand USD | -96.85% |
| 2000 | 1.31 Million USD | 1537.5% |
| 1999 | 80 Thousand USD | -97.56% |
| 1998 | 3.28 Million USD | 24.24% |
| 1997 | 2.64 Million USD | -22.35% |
| 1996 | 3.4 Million USD | -50.0% |
| 1995 | 6.8 Million USD | -18.07% |
| 1994 | 8.3 Million USD | 13.7% |
| 1993 | 7.3 Million USD | 35.19% |
| 1992 | 5.4 Million USD | -15.63% |
| 1991 | 6.4 Million USD | 48.84% |
| 1990 | 4.3 Million USD | -2.27% |
| 1989 | 4.4 Million USD | 46.67% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5155.00 USD | 515.16% |
| 2024 Q1 | 838.00 USD | -45.09% |
| 2023 Q3 | 2000.00 USD | -13.79% |
| 2023 FY | 1526.00 USD | 703.16% |
| 2023 Q2 | 2320.00 USD | 1917.39% |
| 2023 Q4 | 1526.00 USD | -23.7% |
| 2023 Q1 | 115.00 USD | -39.47% |
| 2022 Q1 | 127.00 USD | -43.56% |
| 2022 Q4 | 190.00 USD | -31.65% |
| 2022 Q3 | 278.00 USD | -23.84% |
| 2022 Q2 | 365.00 USD | 187.4% |
| 2022 FY | 190.00 USD | -15.56% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q2 | 1121.00 USD | 0.0% |
| 2021 FY | 225.00 USD | -65.91% |
| 2021 Q3 | 523.00 USD | -53.35% |
| 2021 Q4 | 225.00 USD | -56.98% |
| 2020 FY | 660.00 USD | -66.24% |
| 2020 Q4 | 660.00 USD | -12.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q2 | 1471.00 USD | 0.0% |
| 2020 Q3 | 750.00 USD | -49.01% |
| 2019 FY | 1955.00 USD | 0.0% |
| 2019 Q1 | - USD | 100.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | 22.05 Thousand USD | 0.0% |
| 2019 Q4 | 1955.00 USD | -91.13% |
| 2018 Q4 | -21.09 Thousand USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | 479.00 USD | 3.01% |
| 2017 Q2 | 381.00 USD | -20.46% |
| 2017 Q3 | 336.00 USD | -11.81% |
| 2017 Q4 | 291.00 USD | -13.39% |
| 2017 FY | 291.00 USD | -37.42% |
| 2016 Q4 | 465.00 USD | 8.64% |
| 2016 Q2 | 473.00 USD | 314.91% |
| 2016 FY | 465.00 USD | 138.46% |
| 2016 Q1 | 114.00 USD | -41.54% |
| 2016 Q3 | 428.00 USD | -9.51% |
| 2015 Q1 | 104.00 USD | -36.59% |
| 2015 Q4 | 195.00 USD | 24.2% |
| 2015 FY | 195.00 USD | 18.9% |
| 2015 Q3 | 157.00 USD | 292.5% |
| 2015 Q2 | 40.00 USD | -61.54% |
| 2014 Q4 | 164.00 USD | -27.11% |
| 2014 Q1 | 1000.00 USD | 334.78% |
| 2014 FY | 164.00 USD | -28.7% |
| 2014 Q3 | 225.00 USD | 184.81% |
| 2014 Q2 | 79.00 USD | -92.1% |
| 2013 Q3 | 1277.00 USD | 2.0% |
| 2013 FY | 230.00 USD | -81.18% |
| 2013 Q4 | 230.00 USD | -81.99% |
| 2013 Q2 | 1252.00 USD | -5.86% |
| 2013 Q1 | 1330.00 USD | 8.84% |
| 2012 Q1 | 572.00 USD | 25.44% |
| 2012 Q4 | 1222.00 USD | -4.68% |
| 2012 Q2 | 1091.00 USD | 90.73% |
| 2012 FY | 1222.00 USD | 167.98% |
| 2012 Q3 | 1282.00 USD | 17.51% |
| 2011 FY | 456.00 USD | -56.53% |
| 2011 Q1 | 1088.00 USD | 3.72% |
| 2011 Q2 | 666.00 USD | -38.79% |
| 2011 Q3 | 638.00 USD | -4.2% |
| 2011 Q4 | 456.00 USD | -28.53% |
| 2010 Q4 | 1049.00 USD | 109.58% |
| 2010 FY | 1049.00 USD | -84.62% |
| 2010 Q3 | -10.94 Thousand USD | -7.5% |
| 2010 Q2 | -10.18 Thousand USD | -207.01% |
| 2010 Q1 | 9516.00 USD | 39.55% |
| 2009 Q2 | 4341.00 USD | 98.22% |
| 2009 Q4 | 6819.00 USD | 9504.23% |
| 2009 FY | 6819.00 USD | 112.43% |
| 2009 Q1 | 2190.00 USD | -31.78% |
| 2009 Q3 | 71.00 USD | -98.36% |
| 2008 Q4 | 3210.00 USD | -66.63% |
| 2008 FY | 3210.00 USD | -99.83% |
| 2008 Q1 | 1.9 Million USD | 0.0% |
| 2008 Q2 | 280.45 Thousand USD | -85.26% |
| 2008 Q3 | 9618.00 USD | -96.57% |
| 2007 Q2 | 1.9 Million USD | -89.09% |
| 2007 Q1 | 17.43 Million USD | -17.42% |
| 2007 FY | 1.9 Million USD | -90.99% |
| 2007 Q4 | 1.9 Million USD | 0.0% |
| 2007 Q3 | 1.9 Million USD | -0.03% |
| 2006 Q2 | 23.69 Million USD | 2465.15% |
| 2006 Q1 | 923.74 Thousand USD | 67.5% |
| 2006 Q4 | 21.11 Million USD | -14.48% |
| 2006 FY | 21.11 Million USD | 3728.53% |
| 2006 Q3 | 24.68 Million USD | 4.19% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | 551.47 Thousand USD | 2270.83% |
| 2005 Q1 | 24.97 Thousand USD | 7.36% |
| 2005 Q2 | 23.21 Thousand USD | -7.04% |
| 2005 Q4 | 551.47 Thousand USD | 0.0% |
| 2004 Q4 | 23.26 Thousand USD | 2.13% |
| 2004 Q2 | 3094.00 USD | 90.52% |
| 2004 Q1 | 1624.00 USD | -82.75% |
| 2004 Q3 | 22.77 Thousand USD | 636.1% |
| 2004 FY | 23.26 Thousand USD | 147.01% |
| 2003 Q4 | 9417.00 USD | 0.0% |
| 2003 Q1 | - USD | -100.0% |
| 2003 FY | 9417.00 USD | -99.29% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | 1.33 Million USD | 3137.76% |
| 2002 Q1 | 20.46 Thousand USD | -48.83% |
| 2002 Q2 | 53.39 Thousand USD | 160.85% |
| 2002 Q3 | 52.53 Thousand USD | -1.61% |
| 2002 Q4 | 1.33 Million USD | 2439.34% |
| 2001 Q4 | 40 Thousand USD | -80.95% |
| 2001 FY | 41.2 Thousand USD | -96.85% |
| 2001 Q1 | 1.27 Million USD | -3.05% |
| 2001 Q2 | 1.16 Million USD | -8.66% |
| 2001 Q3 | 210 Thousand USD | -81.9% |
| 2000 Q1 | 80 Thousand USD | 0.0% |
| 2000 Q4 | 1.31 Million USD | -11.49% |
| 2000 Q3 | 1.48 Million USD | 1245.45% |
| 2000 Q2 | 110 Thousand USD | 37.5% |
| 2000 FY | 1.31 Million USD | 1537.5% |
| 1999 Q4 | 80 Thousand USD | -27.27% |
| 1999 Q3 | 110 Thousand USD | -99.73% |
| 1999 FY | 80 Thousand USD | -97.56% |
| 1999 Q1 | 3.18 Million USD | -3.05% |
| 1999 Q2 | 40.03 Million USD | 1158.81% |
| 1998 Q2 | 2.41 Million USD | -8.71% |
| 1998 Q3 | 2.53 Million USD | 4.98% |
| 1998 Q1 | 2.64 Million USD | 0.0% |
| 1998 Q4 | 3.28 Million USD | 29.64% |
| 1998 FY | 3.28 Million USD | 24.24% |
| 1997 Q2 | 3.98 Million USD | -7.44% |
| 1997 Q3 | 3.7 Million USD | -7.04% |
| 1997 Q4 | 2.64 Million USD | -28.65% |
| 1997 FY | 2.64 Million USD | -22.35% |
| 1997 Q1 | 4.3 Million USD | 26.47% |
| 1996 FY | 3.4 Million USD | -50.0% |
| 1996 Q1 | 6.5 Million USD | -4.41% |
| 1996 Q2 | 6.2 Million USD | -4.62% |
| 1996 Q3 | 6 Million USD | -3.23% |
| 1996 Q4 | 3.4 Million USD | -43.33% |
| 1995 Q4 | 6.8 Million USD | -17.07% |
| 1995 Q1 | 8.3 Million USD | 0.0% |
| 1995 Q2 | 8.6 Million USD | 3.61% |
| 1995 Q3 | 8.2 Million USD | -4.65% |
| 1995 FY | 6.8 Million USD | -18.07% |
| 1994 Q4 | 8.3 Million USD | 1.97% |
| 1994 Q1 | 8 Million USD | 9.59% |
| 1994 Q2 | 8.5 Million USD | 6.25% |
| 1994 Q3 | 8.14 Million USD | -4.24% |
| 1994 FY | 8.3 Million USD | 13.7% |
| 1993 Q1 | 4.8 Million USD | -11.11% |
| 1993 Q2 | 4.6 Million USD | -4.17% |
| 1993 FY | 7.3 Million USD | 35.19% |
| 1993 Q3 | 3.9 Million USD | -15.22% |
| 1993 Q4 | 7.3 Million USD | 87.18% |
| 1992 FY | 5.4 Million USD | -15.63% |
| 1992 Q1 | 6.3 Million USD | -1.56% |
| 1992 Q2 | 6.1 Million USD | -3.17% |
| 1992 Q3 | 5.1 Million USD | -16.39% |
| 1992 Q4 | 5.4 Million USD | 5.88% |
| 1991 Q2 | 4.6 Million USD | 6.98% |
| 1991 Q4 | 6.4 Million USD | 23.08% |
| 1991 FY | 6.4 Million USD | 48.84% |
| 1991 Q1 | 4.3 Million USD | 0.0% |
| 1991 Q3 | 5.2 Million USD | 13.04% |
| 1990 Q3 | 4.5 Million USD | -2.17% |
| 1990 FY | 4.3 Million USD | -2.27% |
| 1990 Q4 | 4.3 Million USD | -4.44% |
| 1990 Q1 | 4.8 Million USD | 9.09% |
| 1990 Q2 | 4.6 Million USD | -4.17% |
| 1989 Q2 | 4.4 Million USD | 0.0% |
| 1989 Q4 | 4.4 Million USD | 0.0% |
| 1989 FY | 4.4 Million USD | 46.67% |
| 1989 Q3 | 4.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | 33.939% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 99.922% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.986% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 99.724% |
| Rebus Holdings, Inc. | 5000.00 USD | 69.48% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.999% |
| Qrons Inc. | 420.00 USD | -263.333% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 99.802% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.995% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 99.682% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.987% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.996% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 99.979% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | 98.001% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.999% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 99.893% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | 97.891% |
| Mesoblast Limited | 667.9 Million USD | 100.0% |
| Marizyme, Inc. | 22.01 Million USD | 99.993% |
| Genus plc | 1.02 Billion USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 99.888% |
| Pharming Group N.V. | 462.85 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 99.954% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 99.694% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 99.757% |
| ContraFect Corporation | 20.67 Million USD | 99.993% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 99.609% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 99.601% |
| IMV Inc. | 31.33 Million USD | 99.995% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 99.963% |
| MultiCell Technologies, Inc. | 126.22 USD | -1109.0% |
| ONE Bio Corp. | 70.08 Million USD | 99.998% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 99.838% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.999% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 99.647% |
| Q BioMed Inc. | 3.51 Million USD | 99.957% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.996% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 99.416% |
| Biomind Labs Inc. | 73.81 Thousand USD | 97.933% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 99.895% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.995% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 99.944% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 99.778% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 99.941% |
| GB Sciences, Inc. | 103.44 Thousand USD | 98.525% |
| Alpha Cognition Inc. | 2.45 Million USD | 99.938% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 99.846% |
| Halberd Corporation | 10.13 Thousand USD | 84.937% |
| Enzolytics Inc. | 361.7 Million USD | 100.0% |
| Agentix Corp. | 261.39 Thousand USD | 99.416% |
| Resverlogix Corp. | 8.11 Million USD | 99.981% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 99.919% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.997% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 99.761% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | 93.301% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.983% |
| AVAX Technologies, Inc. | 7.37 Million USD | 99.979% |
| Zenith Capital Corp. | 7410.00 USD | 79.406% |
| Genscript Biotech Corporation | 3.38 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 184.00 USD | -729.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 99.526% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 99.416% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 99.836% |
| Kadimastem Ltd | 2.3 Million USD | 99.934% |
| Helix BioMedix, Inc. | 3.02 Million USD | 99.95% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.997% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.99% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | 97.327% |
| LadRx Corporation | 2.3 Million USD | 99.934% |
| Cell Source, Inc. | 195.17 Thousand USD | 99.218% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.568% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 99.568% |
| NovAccess Global Inc. | 62.24 Thousand USD | 97.549% |
| Affymax, Inc. | 7.44 Million USD | 99.979% |
| Itoco Inc. | 1.4 Million USD | 99.891% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 98.405% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 98.56% |
| Mobile Lads Corp. | 52.00 USD | -2834.615% |
| CytoDyn Inc. | 11.13 Million USD | 99.986% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 98.933% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | 91.465% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 99.604% |
| SYBLEU INC | 330.46 Thousand USD | 99.538% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 99.627% |
| International Stem Cell Corporation | 5.39 Million USD | 99.972% |
| Bioxytran, Inc. | 137.63 Thousand USD | 98.891% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.99% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.991% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 98.068% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 99.824% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 99.98% |
| Neutra Corp. | 2851.00 USD | 46.475% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.995% |
| PureTech Health plc | 693.97 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.981% |
| IXICO plc | 15.84 Million USD | 99.99% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.982% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.999% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 100.0% |